- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Granules India Limited reported a strong Q1 FY27, with revenue up 22% YoY to INR1,477 Cr. EBITDA grew 37% to INR338.9 Cr (22.9% margin), and PAT surged 60% to INR180 Cr. Gross margin remained healthy at 65.6%. Net debt significantly reduced to INR101.2 Cr, and operating cash generation was robust at INR387.4 Cr. Management emphasized a strategic shift towards innovation-led complex generics, now 50% of finished dosages. Gagillapur remediation is complete, with 9 applications awaiting FDA clearance. The Peptide CDMO is scaling, targeting USD 50 million revenue with 30%+ EBITDA in the mid-3rd year. R&D spend will be 5.5-6% of sales. The company expresses confidence in sustained growth and profitability.